Verify a record

Auditing outside this page

For technical diligence and compliance review: recompute the specification digest directly in your own environment using Node.js or any standard crypto library. Any environment that can run SHA-256 on the serialized fields will reproduce the nc-v1 specification hash of the worked example above.

node -e "const {createHash}=require('node:crypto');const t=process.argv[1];console.log(createHash('sha256').update(t).digest('hex'))" "scheme=nc-v1
method=v0.1.0
proposition=A version of the NCCN Clinical Practice Guidelines in Oncology for Non-Small Cell Lung Cancer carrying a version date on or before 2027-07-31 lists sunvozertinib (ZEGFROVY) as a first-line / initial systemic therapy option, at any NCCN category, for EGFR exon 20 insertion mutation-positive metastatic non-squamous NSCLC.
authority=National Comprehensive Cancer Network (NCCN)
rung=5 — Rung 5: Guideline action
deadline=2027-07-31
evidence_cutoff=2026-07-31
threshold=75%
resolution=Resolves YES if any NCCN NSCLC guideline version dated on or before 2027-07-31 names sunvozertinib (or ZEGFROVY) anywhere in the initial-systemic-therapy recommendation set for EGFR exon 20 insertion mutation-positive metastatic non-squamous NSCLC, at any category (1, 2A, 2B, or 3) and whether or not it is marked preferred. The adjudicator reads the NSCLC algorithm page for initial systemic therapy in EGFR exon 20 insertion mutation-positive disease and the corresponding systemic therapy tables, in the latest version dated on or before 2027-07-31. Resolves NO if no such version names it there. Listing confined to subsequent-line or post-progression therapy does NOT count. Access requires free NCCN registration; no clinical judgement about the drug is needed to apply this rule."